2024年AFS会议展示了Implantica AG的RefluxStop®植入物,旨在获得FDA的GERD治疗批准. 2024 AFS meeting showcased Implantica AG's RefluxStop® implant, targeting FDA approval for GERD treatment.

在科罗拉多州举行的2024年美国前肠病学会 (AFS) 会议上,Implantica AG的RefluxStop®植入物获得了显著的关注,超过600名专家讨论了前肠病治疗的创新. Implantica AG's RefluxStop® implant gained significant attention at the 2024 American Foregut Society (AFS) meeting in Colorado, where over 600 experts discussed innovations in foregut disease treatments. 该公司正在寻求FDA批准RefluxStop®,该药物旨在解决数百万美国人的胃食道逆流病 (GERD). The company is pursuing FDA approval for RefluxStop®, which aims to address gastroesophageal reflux disease (GERD) for millions of Americans. 介绍了积极的长期和实际数据,突出说明了该产品在改进GERRD管理方面的潜力。 Positive long-term and real-world data were presented, highlighting the product's potential to improve GERD management.